Company news
Cns Pharmaceuticals, Inc. (NASDAQ:CNSP) news
Every Cns Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
September 1, 2026
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
August 27, 2026
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic T...
August 12, 2026
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation
June 9, 2026
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
June 8, 2026
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transfo...
May 20, 2026
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
May 14, 2026
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
May 4, 2026
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
March 11, 2026
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
March 2, 2026
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
February 17, 2026
CNS Pharmaceuticals Issues Letter to Shareholders
January 27, 2026
CNS Pharmaceuticals Issues Letter to Shareholders
January 27, 2026
CNS Pharmaceuticals Announces CEO Transition
December 17, 2025
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 17, 2025
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Mee...
November 10, 2025
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 15, 2025
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 14, 2025
CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
July 22, 2025
CNS Pharmaceuticals Announces Reverse Stock Split
July 18, 2025
CNS Pharmaceuticals Announces Reverse Stock Split
July 18, 2025
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
July 9, 2025
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287
June 25, 2025
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TP...
June 24, 2025
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
June 5, 2025
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 16, 2025
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
May 13, 2025
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
May 13, 2025
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
April 1, 2025
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
April 1, 2025
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
March 25, 2025
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
February 26, 2025
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
February 20, 2025
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
February 18, 2025
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 10, 2025
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
December 5, 2024
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Re...
November 26, 2024
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Re...
November 25, 2024
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO...
November 18, 2024
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 15, 2024
CNS Pharmaceuticals : Quarterly Report for Quarter Ending September, 30, 2024 (Form 10-Q)
November 14, 2024
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
November 4, 2024
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
November 1, 2024
CNS Pharmaceuticals : Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At The Market Under Nasdaq Rules ...
October 24, 2024
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At the Market under Nasdaq Rules
October 24, 2024
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
October 23, 2024
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
October 10, 2024
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
October 8, 2024